PT  - JOURNAL ARTICLE
AU  - Ulrich Costabel
TI  - The changing treatment landscape in idiopathic pulmonary fibrosis
AID  - 10.1183/09059180.00011414
DP  - 2015 Mar 01
TA  - European Respiratory Review
PG  - 65--68
VI  - 24
IP  - 135
4099  - http://err.ersjournals.com/content/24/135/65.short
4100  - http://err.ersjournals.com/content/24/135/65.full
SO  - EUROPEAN RESPIRATORY REVIEW2015 Mar 01; 24
AB  - Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive and irreversible fibrotic disease of the lung that has greatly frustrated clinicians for a long time. The prognosis of IPF (median survival 2–5 years following diagnosis) is poorer than that of some cancers and for many years no significant advances were made in its management. However, between 2011 and 2014 a number of pivotal developments were made that have improved the outlook for patients with IPF. Herein, we review this rapidly changing landscape, discussing key events whilst still acknowledging that IPF remains a challenging disease to diagnose and manage. Idiopathic pulmonary fibrosis has become a treatable disease, with two drugs now approved for this indication http://ow.ly/GhCEE